Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial.
Brett L HoustonPatrick R LawlerEwan C GoligherMichael E FarkouhCharlotte BradburyMarc CarrierVlad DzavikDean A FergussonRobert A FowlerJean-Phillippe GalanaudPeter L GrossEmily G McDonaldMansoor HusainSusan R KahnAnand KumarJohn MarshallSrinivas MurthyArthur S SlutskyAlexis F TurgeonScott M BerryRobert S RosensonJorge EscobedoJose C NicolauLindsay BondBridget-Anne KirwanSophie de BrouwerRyan ZarychanskiPublished in: Clinical trials (London, England) (2020)
Using an adaptive trial design, the Anti-Thrombotic Therapy To Ameliorate Complications of COVID-19 trial will establish whether therapeutic anticoagulation can reduce mortality and/or avoid the need for mechanical ventilation in patients hospitalized with COVID-19. Leveraging existing networks to recruit sites will increase enrollment and mitigate enrollment risk in sites with declining COVID-19 cases.
Keyphrases
- coronavirus disease
- sars cov
- mechanical ventilation
- randomized controlled trial
- study protocol
- end stage renal disease
- clinical trial
- newly diagnosed
- acute respiratory distress syndrome
- phase iii
- respiratory syndrome coronavirus
- health insurance
- chronic kidney disease
- atrial fibrillation
- venous thromboembolism
- systematic review
- prognostic factors
- peritoneal dialysis
- cardiovascular disease
- stem cells
- extracorporeal membrane oxygenation
- mesenchymal stem cells
- open label